Key Takeaways
- Israel escalates conflict with Iran, striking a naval base linked to submarine development and reporting the deployment of 15,000 bombs against Iranian targets.
- Merck & Co (MRK) enters a definitive agreement to acquire Terns Pharmaceuticals (TERN) for $6.7 billion ($53.00 per share) to bolster its oncology and hematology pipeline.
- The Pentagon secures massive production hikes for munitions and missile components, including a fourfold increase in THAAD seeker production from BAE Systems (BAESY).
- US Mortgage Applications plunged 10.5% for the week ending March 20, as the 30-year fixed mortgage rate climbed to 6.43%.
- Diplomatic efforts for a ceasefire are reportedly underway, led by US envoys aiming for a one-month pause in hostilities.
Geopolitical Escalation and Defense Response
The Israel Defense Forces (IDF) reported a significant strike on an Iranian navy base today, citing the facility's role in submarine development as the primary catalyst. Israel's Defense Minister revealed that the military has dropped 15,000 bombs on Iran during the current engagement, a figure four times higher than the previous 12-day conflict.
In response to the regional instability, the U.S. Department of Defense has moved to rapidly scale up domestic munitions production. BAE Systems (BAESY) signed a seven-year agreement to quadruple the production of THAAD infrared seekers. Simultaneously, the Pentagon reached agreements with Lockheed Martin (LMT) and Honeywell (HON) to accelerate the manufacturing of Precision Strike Missiles and general munitions supplies.
Regional fallout continues as Iraq’s Prime Minister ordered the Foreign Ministry to summon the U.S. Chargé d’Affaires. The move serves as a formal protest against U.S. strikes on Iraqi military units, further complicating the security architecture in the Middle East.
Merck Bolsters Hematology Portfolio with $6.7B Deal
Merck & Co (MRK) has announced the acquisition of Terns Pharmaceuticals (TERN) for $53.00 per share in cash. The deal values Terns at an equity value of approximately $6.7 billion, representing a 31% premium over its 60-day volume-weighted average price.
The acquisition centers on TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor currently in development for chronic myeloid leukemia (CML). Merck expects to finalize the transaction in the second quarter of 2026, incurring a one-time R&D charge of $5.8 billion, or roughly $2.35 per share.
Global Macroeconomic and Market Developments
US housing demand saw a sharp contraction as MBA Mortgage Applications fell 10.5%, following a previous decline of 10.9%. The 30-year mortgage rate rose to 6.43%, weighing heavily on consumer sentiment despite a general rise in global equities fueled by ceasefire rumors.
In Asia, Japan is preparing a stop-gap budget bill valued at 8 trillion yen to address immediate fiscal needs. On the diplomatic front, China’s Premier Li held a phone call with the Dutch Prime Minister to discuss bilateral relations, while German chemical unions signaled that wage discussions are nearing a formal agreement.
Reports suggest a potential diplomatic breakthrough as US special envoy Steve Witkoff and Jared Kushner work on a 15-point ceasefire mechanism. The proposed deal aims for a one-month cessation of hostilities to allow for deeper negotiations, mimicking previous frameworks used in Gaza and Lebanon.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.